Head and Neck Cancers: Overview and Risk Factors

Head and neck cancers represent a distinct group of malignancies that arise in the anatomical structures above the clavicle, excluding the brain and spinal cord. These cancers collectively account for approximately 4% of all cancers diagnosed in the United States each year, according to the National Cancer Institute (NCI). Understanding their classification, underlying mechanisms, and risk factors is essential for appropriate clinical evaluation and timely intervention. This page covers the major subtypes, how these cancers develop, clinical scenarios that prompt evaluation, and the boundaries that guide diagnosis and staging decisions.

Definition and Scope

Head and neck cancers are classified by their anatomical site of origin. The National Cancer Institute identifies the following primary sites:

  1. Oral cavity — lips, tongue, gums, floor of the mouth, hard palate, and buccal mucosa
  2. Pharynx — nasopharynx (upper), oropharynx (middle), hypopharynx (lower)
  3. Larynx — vocal cords, supraglottis, subglottis
  4. Nasal cavity and paranasal sinuses — maxillary, ethmoid, sphenoid, and frontal sinuses
  5. Salivary glands — parotid, submandibular, and sublingual glands
  6. Thyroid and parathyroid glands — often classified separately; see dedicated coverage at Thyroid Cancer

More than 90% of head and neck cancers are squamous cell carcinomas (SCC), arising from the mucosal epithelium lining these structures (NCI, Head and Neck Cancer Treatment). Adenocarcinomas, mucoepidermoid carcinomas, and adenoid cystic carcinomas occur in salivary gland tumors but represent a smaller proportion of cases.

The American Joint Committee on Cancer (AJCC) provides site-specific TNM staging systems for each anatomical subtype, reflecting that a tumor in the nasopharynx behaves biologically and prognostically differently from one in the larynx. Site-specific staging is essential, not interchangeable across subsites. The broader regulatory context for oncology — including FDA approval pathways for oncology drugs and CMS coverage criteria — shapes which diagnostic and treatment protocols are applied in clinical practice.

How It Works

Carcinogenesis in Mucosal Epithelium

Head and neck squamous cell carcinoma develops through progressive accumulation of genetic mutations in the mucosal lining. The two dominant carcinogenic pathways are:

Epstein-Barr Virus (EBV) and Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) follows a third pathway strongly associated with Epstein-Barr virus (EBV) infection, particularly in populations of Southeast Asian and Chinese descent. EBV latent membrane proteins dysregulate cell proliferation and apoptotic pathways, contributing to malignant transformation. NPC is staged using a distinct AJCC schema that accounts for the unique lymphatic drainage patterns of the nasopharynx.

Salivary Gland Tumors

Salivary gland malignancies arise from ductal and acinar epithelial cells. Mucoepidermoid carcinoma is the most common malignant salivary gland tumor; adenoid cystic carcinoma is notable for perineural invasion and late distant metastasis even after apparent local control.

Common Scenarios

Four clinical presentations account for the large majority of head and neck cancer evaluations:

  1. Persistent oral lesion or throat soreness — A mucosal lesion, white patch (leukoplakia), or red patch (erythroplakia) lasting more than 3 weeks warrants tissue evaluation. Erythroplakia carries a malignant transformation rate substantially higher than leukoplakia (NCI Oral Cancer Fact Sheet).
  2. Neck mass in an adult — A painless, unilateral neck mass persisting beyond 3 weeks in an adult is considered a metastatic lymph node from a head and neck primary until proven otherwise. Evaluation typically follows the pathway described in Imaging for Cancer and Biopsy Types and What to Expect.
  3. Hoarseness or voice change lasting more than 3 weeks — Persistent hoarseness in a tobacco user prompts laryngoscopic evaluation for laryngeal SCC.
  4. Dysphagia with unexplained weight loss — Hypopharyngeal or oropharyngeal cancers commonly present with progressive swallowing difficulty. The intersection of dysphagia and involuntary weight loss is discussed further at Unexplained Weight Loss and Fatigue as Warning Signs.

Occupational exposures also generate distinct scenarios. Workers with sustained exposure to wood dust, nickel compounds, or formaldehyde carry elevated risk for paranasal sinus and nasal cavity cancers. The National Institute for Occupational Safety and Health (NIOSH) classifies wood dust as a Group 1 human carcinogen for nasal adenocarcinoma, consistent with the International Agency for Research on Cancer (IARC) classification.

Decision Boundaries

HPV-Positive vs. HPV-Negative Oropharyngeal SCC

The AJCC 8th Edition (2017) introduced a separate staging system for p16-positive (HPV-associated) oropharyngeal SCC, reflecting its meaningfully different survival profile. A patient with HPV-positive disease and extensive nodal involvement may be classified at a lower stage — and treated with potentially less morbid protocols — than an HPV-negative patient with identical tumor burden. Molecular testing for p16 by immunohistochemistry, followed by HPV in situ hybridization or PCR confirmation, is now standard at most academic oncology centers.

Early-Stage vs. Locally Advanced Disease

The clinical boundary between early-stage (AJCC Stage I–II) and locally advanced (Stage III–IVB) head and neck SCC determines the primary treatment modality:

Screening Thresholds and High-Risk Subgroups

No population-wide screening program for head and neck cancers exists in the United States as of the AJCC 8th Edition era; the United States Preventive Services Task Force (USPSTF) has not issued a recommendation for routine oral cancer screening in asymptomatic adults. High-risk subgroups — including long-term tobacco users, heavy alcohol users, immunocompromised individuals, and those with prior head and neck SCC — are monitored through interval clinical examination rather than standardized population screening. The distinction between opportunistic examination findings and formal screening is clinically and regulatorily significant, as it affects coding, reimbursement, and documentation requirements under CMS guidelines.

Genetic predisposition plays a smaller role in head and neck cancers than in cancers such as breast or colorectal, but Fanconi anemia is a recognized hereditary condition associated with markedly elevated squamous cell carcinoma risk in the head and neck region. Individuals with known Fanconi anemia require specialized surveillance protocols. For broader context on hereditary cancer risk assessment, Genetic Testing and Cancer Risk covers the evaluation framework in detail.

For a comprehensive introduction to how cancer is classified and staged across all sites, the oncology resource index provides structured navigation to staging, diagnosis, and treatment reference content.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)